Mukai et al.’s 499-person Phase 2b schizophrenia trial tested whether higher, sustained PDE10A inhibition could turn MK-8189 into a non-D2 antipsychotic; it did not. At week 6, MK-8189 missed the PANSS total endpoint at 16 mg (−2.8 points vs. placebo; 95% CI −8.3 to 2.6; P = 0.241) and 24 mg (−0.7 points; 95% CI …
A 2026 analysis of 174 people with non-affective first-episode psychosis found that cognitive reserve was tied to 3 signals available near illness onset: age at onset, family history of psychosis, and polygenic liability for educational attainment. Adding the education polygenic score raised the model’s adjusted R² from 13.5% to 17.7%, a real but modest gain …
A 2026 hospital MRI study found that the left paracingulate sulcus was present in 31 of 109 catatonia patients (28%) vs. 171 of 323 psychiatric controls without catatonia (53%), a left-hemisphere group effect that survived adjustment for age, sex, scanner, brain volume, benzodiazepines, and antipsychotics.1 Research Highlights Left PCS signal: left paracingulate sulcus (PCS) presence …
A 2026 eLife computational study modeled classical psychedelics by increasing a network state variable from alpha = 0 to alpha = 1, shifting perception from bottom-up sensory inference toward top-down generative replay. The result is a useful but still unproven oneirogen model: hallucinations look less like random noise and more like wake-time replay of a …
First-generation antipsychotic (FGA) shortages are not just pharmacy annoyances; they force medication changes in people who may have taken years to stabilize on a tolerable regimen. Research Highlights 95,968 patients: Tabah 2026 used Komodo claims data to study people with psychotic-spectrum diagnoses taking shortage-affected first-generation antipsychotics. Switching was not evenly distributed: molindone reached 100% switching, …
Patients with schizophrenia have substantially elevated dementia risk compared to the general population — roughly 2-3 times the age-adjusted rate — but the specific drivers within the schizophrenia population have been less well characterized. A 2026 case-control study by Ho et al. used population-based data to identify which factors specifically elevate dementia risk among schizophrenia …
Clozapine is the only medication with proven efficacy for treatment-resistant schizophrenia, yet most eligible patients wait years before starting it. A 2026 paper by Perfalk and colleagues trains a machine-learning model on routine electronic health record data to flag candidates earlier.1 Research Highlights Clozapine is the only evidence-based treatment for treatment-resistant schizophrenia (TRS), but the …